Shots:

• Exact & Mayo has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening- incidence- and mortality rates. The Voyage study will provide additional- real-world evidence demonstrating the clinical impact of Cologuard & position it as SoC in colorectal cancer screening
• The Voyage study is a prospective- observational study- enrolling 150-000+ people with a valid Cologuard order and follow them for at least seven years to evaluate clinical outcomes
• Cologuard is the only FDA-approved- at-home colorectal cancer screening test having the potential to improve screening rates in patients with colorectal cancer and has received FDA’s approval in Aug’14

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology